Patient-friendly dosing regimen proves a winner for Eylea

9 September 2022
eye_ophthalmic_big

A less cumbersome dosing schedule for Eylea (aflibercept) has been shown safe and effective in late-stage trials, boosting its developers' chances of defending market share.

Drugmakers Regeneron Pharmaceuticals (Nasdaq: REGN) and Bayer (BAYN: DE) offer the therapy to treat serious ophthalmic conditions, including diabetic macular edema (DME) and wet age-related macular degeneration (AMD).

Now, results from the PHOTON and PULSAR trials show that a four-times higher dose, offered at 12 and 16-week dosing regimens, was safe and effective compared with the usual eight-week interval.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology